Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

PGNX / Progenics Pharmaceuticals, Inc. / FEDERATED INVESTORS INC /PA/ - 3G/A (Passive Investment)

2018-02-16 sec.gov
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 14*) PROGENICS PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 743187106 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

Progenics: Market Reticence Creates Rare Opportunity

2018-02-16 seekingalpha
On February 12th, Progenics Pharmaceuticals (PGNX) delivered a presentation at the BIO CEO and Investor Conference. The company reiterated the findings from the trial of Azedra, its treatment for two extremely rare adrenal gland cancers. The data is already known, so that was largely recapitulation. (12-1)

PGNX / Progenics Pharmaceuticals, Inc. / FEDERATED INVESTORS INC /PA/ - 3G/A (Passive Investment)

2018-02-15 sec.gov
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 14*) PROGENICS PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 743187106 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

PGNX / Progenics Pharmaceuticals, Inc. / Broadfin Capital, LLC - 3G/A (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 5)*     Progenics Pharmaceuticals, Inc. (Name of Issuer)     Common Stock, par value $.0013 per share (Title of Class of Securities)     743187106 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b)   [X

PGNX / Progenics Pharmaceuticals, Inc. / Broadfin Capital, LLC - 3G/A (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 5)*     Progenics Pharmaceuticals, Inc. (Name of Issuer)     Common Stock, par value $.0013 per share (Title of Class of Securities)     743187106 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b)   [X

PGNX / Progenics Pharmaceuticals, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 6 PROGENICS PHARMACEUTICALS INC COMMON STOCK Cusip #743187106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #743187106 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 1,855,156 Item 8: 0 Item 9: 1,855,156 Item 11: 2.

PGNX / Progenics Pharmaceuticals, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 6 PROGENICS PHARMACEUTICALS INC COMMON STOCK Cusip #743187106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #743187106 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 1,855,156 Item 8: 0 Item 9: 1,855,156 Item 11: 2.

PGNX / Progenics Pharmaceuticals, Inc. / VANGUARD GROUP INC - 3G (Passive Investment)

2018-02-09 sec.gov
progenicspharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 0 )*       Name of issuer:  Progenics Pharmaceuticals Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  743187106     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedu

PGNX / Progenics Pharmaceuticals, Inc. / VANGUARD GROUP INC - 3G (Passive Investment)

2018-02-09 sec.gov
progenicspharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 0 )*       Name of issuer:  Progenics Pharmaceuticals Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  743187106     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedu

2 Small Biotechs To Buy On This Dip

2018-02-08 seekingalpha
The market has been a roller coaster for investors so far in February which major daily moves throughout the month. (73-5)

Trump On Healthcare Industry: State Of The Union Promises Good Times For Biotech Investors

2018-02-01 seekingalpha
President Trump discussed the pharmaceutical industry during his State of the Union address on Jan. 30. (23-1)

PGNX / Progenics Pharmaceuticals, Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-19 sec.gov
us7431871067_011718.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) PROGENICS PHARMACEUTICALS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 743187106 -------------------------------------------------------- (CUSIP Number) December 31, 2017 ----------------------------------------

PGNX / Progenics Pharmaceuticals, Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-19 sec.gov
us7431871067_011718.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) PROGENICS PHARMACEUTICALS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 743187106 -------------------------------------------------------- (CUSIP Number) December 31, 2017 ----------------------------------------

Progenics Pharmaceuticals: An Underappreciated Company You Can't Afford To Ignore

2018-01-18 seekingalpha
Risk and reward assessment here in the near to long term is highly favorable for the speculative investor. (32-1)

PGNX / Progenics Pharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-08 fintel.io
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has 146 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 59,460,929 shares. Largest shareholders include Federated Investors Inc /pa/, BlackRock Inc., Vanguard Group Inc, Eagle Asset Management Inc, State Street Corp, Baker Brothers Advisors LP, Fmr Llc, Pinnacle Associates Ltd, Ardsley Advisory Partners, and Phocas Financial Corp. (57-2)


CUSIP: 743187106